Assessment of quality of life and safety in postmenopausal breast cancer patients receiving letrozole as an early adjuvant treatment

Yongsik Jung, Soo Jung Lee, Juneyoung Lee, Woo Chul Noh, Seok Jin Nam, Byeong Woo Park, Young Tae Bae, Sung Soo Kang, Heung Kyu Park, Jung Han Yoon, Je Ryong Kim, Se Hun Cho, Lee Su Kim, Byung In Moon, Sung Hoo Jung, Chol Wan Lim, Sung Yong Kim, Ho Yong Park, Jeongyoon Song, Kwang Man LeeSung Hwan Park, Joon Jeong, Hae Lin Park, Sung Won Kim, Beom Seok Kwak, Sun Hee Kang, Young Up Cho, Geum Hee Gwak, Yong Lae Park, Sang Wook Kim, Sehwan Han

Research output: Contribution to journalArticle

Abstract

Purpose: There are few reports from Asian countries about the long-term results of aromatase inhibitor adjuvant treatment for breast cancer. This observational study aimed to evaluate the long-term effects of letrozole in postmenopausal Korean women with operable breast cancer. Methods: Self-reported quality of life (QoL) scores were serially assessed for 3 years during adjuvant letrozole treatment using the Korean version of the Functional Assessment of Cancer Therapy-Breast questionnaires (version 3). Changes in bone mineral density (BMD) and serum cholesterol levels were also examined. Results: All 897 patients received the documented informed consent form and completed a baseline questionnaire before treatment. Adjuvant chemotherapy was administered to 684 (76.3%) subjects, and 410 (45.7%) and 396 (44.1%) patients had stage I and II breast cancer, respectively. Each patient completed questionnaires at 3, 6, 12, 18, 24, 30, and 36 months after enrollment. Of 897 patients, 749 (83.5%) completed the study. The dropout rate was 16.5%. The serial trial outcome index, the sum of the physical and functional well-being subscales, increased gradually and significantly from baseline during letrozole treatment (p< 0.001). The mean serum cholesterol level increased significantly from 199 to 205 after 36 months (p= 0.042). The mean BMD significantly decreased from –0.39 at baseline to –0.87 after 36 months (p< 0.001). Conclusion: QoL gradually improved during letrozole treatment. BMD and serum cholesterol level changes were similar to those in Western countries, indicating that adjuvant letrozole treatment is well tolerated in Korean women, with minimal ethnic variation.

Original languageEnglish
Pages (from-to)182-189
Number of pages8
JournalJournal of Breast Cancer
Volume21
Issue number2
DOIs
Publication statusPublished - 2018 Jun 1

Fingerprint

letrozole
Quality of Life
Breast Neoplasms
Safety
Bone Density
Cholesterol
Therapeutics
Serum
Consent Forms
Aromatase Inhibitors
Adjuvant Chemotherapy
Observational Studies

Keywords

  • Breast neoplasms
  • Letrozole
  • Quality of life
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Assessment of quality of life and safety in postmenopausal breast cancer patients receiving letrozole as an early adjuvant treatment. / Jung, Yongsik; Lee, Soo Jung; Lee, Juneyoung; Noh, Woo Chul; Nam, Seok Jin; Park, Byeong Woo; Bae, Young Tae; Kang, Sung Soo; Park, Heung Kyu; Yoon, Jung Han; Kim, Je Ryong; Cho, Se Hun; Kim, Lee Su; Moon, Byung In; Jung, Sung Hoo; Lim, Chol Wan; Kim, Sung Yong; Park, Ho Yong; Song, Jeongyoon; Lee, Kwang Man; Park, Sung Hwan; Jeong, Joon; Park, Hae Lin; Kim, Sung Won; Kwak, Beom Seok; Kang, Sun Hee; Cho, Young Up; Gwak, Geum Hee; Park, Yong Lae; Kim, Sang Wook; Han, Sehwan.

In: Journal of Breast Cancer, Vol. 21, No. 2, 01.06.2018, p. 182-189.

Research output: Contribution to journalArticle

Jung, Y, Lee, SJ, Lee, J, Noh, WC, Nam, SJ, Park, BW, Bae, YT, Kang, SS, Park, HK, Yoon, JH, Kim, JR, Cho, SH, Kim, LS, Moon, BI, Jung, SH, Lim, CW, Kim, SY, Park, HY, Song, J, Lee, KM, Park, SH, Jeong, J, Park, HL, Kim, SW, Kwak, BS, Kang, SH, Cho, YU, Gwak, GH, Park, YL, Kim, SW & Han, S 2018, 'Assessment of quality of life and safety in postmenopausal breast cancer patients receiving letrozole as an early adjuvant treatment', Journal of Breast Cancer, vol. 21, no. 2, pp. 182-189. https://doi.org/10.4048/jbc.2018.21.2.182
Jung, Yongsik ; Lee, Soo Jung ; Lee, Juneyoung ; Noh, Woo Chul ; Nam, Seok Jin ; Park, Byeong Woo ; Bae, Young Tae ; Kang, Sung Soo ; Park, Heung Kyu ; Yoon, Jung Han ; Kim, Je Ryong ; Cho, Se Hun ; Kim, Lee Su ; Moon, Byung In ; Jung, Sung Hoo ; Lim, Chol Wan ; Kim, Sung Yong ; Park, Ho Yong ; Song, Jeongyoon ; Lee, Kwang Man ; Park, Sung Hwan ; Jeong, Joon ; Park, Hae Lin ; Kim, Sung Won ; Kwak, Beom Seok ; Kang, Sun Hee ; Cho, Young Up ; Gwak, Geum Hee ; Park, Yong Lae ; Kim, Sang Wook ; Han, Sehwan. / Assessment of quality of life and safety in postmenopausal breast cancer patients receiving letrozole as an early adjuvant treatment. In: Journal of Breast Cancer. 2018 ; Vol. 21, No. 2. pp. 182-189.
@article{6608a7b42d1e44958188b775f78c9880,
title = "Assessment of quality of life and safety in postmenopausal breast cancer patients receiving letrozole as an early adjuvant treatment",
abstract = "Purpose: There are few reports from Asian countries about the long-term results of aromatase inhibitor adjuvant treatment for breast cancer. This observational study aimed to evaluate the long-term effects of letrozole in postmenopausal Korean women with operable breast cancer. Methods: Self-reported quality of life (QoL) scores were serially assessed for 3 years during adjuvant letrozole treatment using the Korean version of the Functional Assessment of Cancer Therapy-Breast questionnaires (version 3). Changes in bone mineral density (BMD) and serum cholesterol levels were also examined. Results: All 897 patients received the documented informed consent form and completed a baseline questionnaire before treatment. Adjuvant chemotherapy was administered to 684 (76.3{\%}) subjects, and 410 (45.7{\%}) and 396 (44.1{\%}) patients had stage I and II breast cancer, respectively. Each patient completed questionnaires at 3, 6, 12, 18, 24, 30, and 36 months after enrollment. Of 897 patients, 749 (83.5{\%}) completed the study. The dropout rate was 16.5{\%}. The serial trial outcome index, the sum of the physical and functional well-being subscales, increased gradually and significantly from baseline during letrozole treatment (p< 0.001). The mean serum cholesterol level increased significantly from 199 to 205 after 36 months (p= 0.042). The mean BMD significantly decreased from –0.39 at baseline to –0.87 after 36 months (p< 0.001). Conclusion: QoL gradually improved during letrozole treatment. BMD and serum cholesterol level changes were similar to those in Western countries, indicating that adjuvant letrozole treatment is well tolerated in Korean women, with minimal ethnic variation.",
keywords = "Breast neoplasms, Letrozole, Quality of life, Treatment",
author = "Yongsik Jung and Lee, {Soo Jung} and Juneyoung Lee and Noh, {Woo Chul} and Nam, {Seok Jin} and Park, {Byeong Woo} and Bae, {Young Tae} and Kang, {Sung Soo} and Park, {Heung Kyu} and Yoon, {Jung Han} and Kim, {Je Ryong} and Cho, {Se Hun} and Kim, {Lee Su} and Moon, {Byung In} and Jung, {Sung Hoo} and Lim, {Chol Wan} and Kim, {Sung Yong} and Park, {Ho Yong} and Jeongyoon Song and Lee, {Kwang Man} and Park, {Sung Hwan} and Joon Jeong and Park, {Hae Lin} and Kim, {Sung Won} and Kwak, {Beom Seok} and Kang, {Sun Hee} and Cho, {Young Up} and Gwak, {Geum Hee} and Park, {Yong Lae} and Kim, {Sang Wook} and Sehwan Han",
year = "2018",
month = "6",
day = "1",
doi = "10.4048/jbc.2018.21.2.182",
language = "English",
volume = "21",
pages = "182--189",
journal = "Journal of Breast Cancer",
issn = "1738-6756",
publisher = "Korean Breast Cancer Society",
number = "2",

}

TY - JOUR

T1 - Assessment of quality of life and safety in postmenopausal breast cancer patients receiving letrozole as an early adjuvant treatment

AU - Jung, Yongsik

AU - Lee, Soo Jung

AU - Lee, Juneyoung

AU - Noh, Woo Chul

AU - Nam, Seok Jin

AU - Park, Byeong Woo

AU - Bae, Young Tae

AU - Kang, Sung Soo

AU - Park, Heung Kyu

AU - Yoon, Jung Han

AU - Kim, Je Ryong

AU - Cho, Se Hun

AU - Kim, Lee Su

AU - Moon, Byung In

AU - Jung, Sung Hoo

AU - Lim, Chol Wan

AU - Kim, Sung Yong

AU - Park, Ho Yong

AU - Song, Jeongyoon

AU - Lee, Kwang Man

AU - Park, Sung Hwan

AU - Jeong, Joon

AU - Park, Hae Lin

AU - Kim, Sung Won

AU - Kwak, Beom Seok

AU - Kang, Sun Hee

AU - Cho, Young Up

AU - Gwak, Geum Hee

AU - Park, Yong Lae

AU - Kim, Sang Wook

AU - Han, Sehwan

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Purpose: There are few reports from Asian countries about the long-term results of aromatase inhibitor adjuvant treatment for breast cancer. This observational study aimed to evaluate the long-term effects of letrozole in postmenopausal Korean women with operable breast cancer. Methods: Self-reported quality of life (QoL) scores were serially assessed for 3 years during adjuvant letrozole treatment using the Korean version of the Functional Assessment of Cancer Therapy-Breast questionnaires (version 3). Changes in bone mineral density (BMD) and serum cholesterol levels were also examined. Results: All 897 patients received the documented informed consent form and completed a baseline questionnaire before treatment. Adjuvant chemotherapy was administered to 684 (76.3%) subjects, and 410 (45.7%) and 396 (44.1%) patients had stage I and II breast cancer, respectively. Each patient completed questionnaires at 3, 6, 12, 18, 24, 30, and 36 months after enrollment. Of 897 patients, 749 (83.5%) completed the study. The dropout rate was 16.5%. The serial trial outcome index, the sum of the physical and functional well-being subscales, increased gradually and significantly from baseline during letrozole treatment (p< 0.001). The mean serum cholesterol level increased significantly from 199 to 205 after 36 months (p= 0.042). The mean BMD significantly decreased from –0.39 at baseline to –0.87 after 36 months (p< 0.001). Conclusion: QoL gradually improved during letrozole treatment. BMD and serum cholesterol level changes were similar to those in Western countries, indicating that adjuvant letrozole treatment is well tolerated in Korean women, with minimal ethnic variation.

AB - Purpose: There are few reports from Asian countries about the long-term results of aromatase inhibitor adjuvant treatment for breast cancer. This observational study aimed to evaluate the long-term effects of letrozole in postmenopausal Korean women with operable breast cancer. Methods: Self-reported quality of life (QoL) scores were serially assessed for 3 years during adjuvant letrozole treatment using the Korean version of the Functional Assessment of Cancer Therapy-Breast questionnaires (version 3). Changes in bone mineral density (BMD) and serum cholesterol levels were also examined. Results: All 897 patients received the documented informed consent form and completed a baseline questionnaire before treatment. Adjuvant chemotherapy was administered to 684 (76.3%) subjects, and 410 (45.7%) and 396 (44.1%) patients had stage I and II breast cancer, respectively. Each patient completed questionnaires at 3, 6, 12, 18, 24, 30, and 36 months after enrollment. Of 897 patients, 749 (83.5%) completed the study. The dropout rate was 16.5%. The serial trial outcome index, the sum of the physical and functional well-being subscales, increased gradually and significantly from baseline during letrozole treatment (p< 0.001). The mean serum cholesterol level increased significantly from 199 to 205 after 36 months (p= 0.042). The mean BMD significantly decreased from –0.39 at baseline to –0.87 after 36 months (p< 0.001). Conclusion: QoL gradually improved during letrozole treatment. BMD and serum cholesterol level changes were similar to those in Western countries, indicating that adjuvant letrozole treatment is well tolerated in Korean women, with minimal ethnic variation.

KW - Breast neoplasms

KW - Letrozole

KW - Quality of life

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85049051661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049051661&partnerID=8YFLogxK

U2 - 10.4048/jbc.2018.21.2.182

DO - 10.4048/jbc.2018.21.2.182

M3 - Article

AN - SCOPUS:85049051661

VL - 21

SP - 182

EP - 189

JO - Journal of Breast Cancer

JF - Journal of Breast Cancer

SN - 1738-6756

IS - 2

ER -